Necitumumab
Based on 1 Customer Validation
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.90%
- CAS No.: 906805-06-9
- Masse moléculaire:144.78 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform EGFR
More
Activité biologique
Human IgG1 kappa
Human
ERBB1/EGFR/HER1
Necitumumab specifically binds to the EGF binding site of human EGFR with high affinity (dissociation constant 0.32 nM) and blocks ligand binding with an IC50 of 1-2 nM[1].
Necitumumab neutralizes ligand-induced EGFR phosphorylation with an IC50 of 1.5-3 nM[1].
Necitumumab inhibits the proliferation of EGFR-dependent colorectal tumour cells with an IC50 of 0.8-1.0 nM[1].
Necitumumab induces EGFR internalization and degradation, and triggers antibody-dependent cellular cytotoxicity in EGFR-expressing human cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic mice with A549 and NCI-H1650 xenograft (5-6 week; female)[2]
-
Dosage:60 mg/kg
-
Administration:I.p.; twice a week for 2 weeks
-
Result:Reduced tumor volume.
Increased Ki-67-positive.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human ERBB1/EGFR/HER1, His Tag can bind Necitumumab. The EC50 for this effect is 11.47 ng/mL. -
Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Necitumumab (anti-ERBB1/EGFR/HER1) (HY-P9964). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 906805-06-9
-
Appearance Liquid
-
Masse moléculaire 144.78 kDa
-
Color Colorless to light yellow
-
SMILES
[Necitumumab]
-
Synonyms
11F8; IMC-11F8; LY3012211
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Garnock-Jones KP, et al. Necitumumab: First Global Approval. Drugs. 2016;76(2):283-289. [Content Brief]
[2]. Samakoglu S, et al. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)